Ianalumab's Road to Approval for Sjogren's Looks Bumpier

(MedPage Today) -- Findings from a pair of randomized trials in Sjögren's disease with the anti-B cell biologic ianalumab have now been published and it's no longer clear that they're sufficient to support regulatory approvals. The two trials...